首页> 美国卫生研究院文献>Annals of Vascular Diseases >Molecular Pharmacological Approaches for Treating Abdominal Aortic Aneurysm
【2h】

Molecular Pharmacological Approaches for Treating Abdominal Aortic Aneurysm

机译:治疗腹主动脉瘤的分子药理学方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abdominal aortic aneurysm (AAA) is considered to be a potent life-threatening disorder in elderly individuals. Although many patients with a small AAA are detected during routine abdominal screening, there is no effective therapeutic option to prevent the progression or regression of AAA in the clinical setting. Recent advances in molecular biology have led to the identification of several important molecules, including microRNA and transcription factor, in the process of AAA formation. Regulation of these factors using nucleic acid drugs is expected to be a novel therapeutic option for AAA. Nucleic acid drugs can bind to target factors, mRNA, microRNA, and transcription factors in a sequence-specific fashion, resulting in a loss of function of the target molecule at the transcriptional or posttranscriptional level. Of note, inhibition of a transcription factor using a decoy strategy effectively suppresses experimental AAA formation, by regulating the expression of several genes associated with the disease progression. This review focuses on recent advances in molecular therapy of using nucleic acid drugs to treat AAA.
机译:腹主动脉瘤(AAA)被认为是严重威胁生命的老年人疾病。尽管在常规的腹部筛查过程中发现了许多AAA小的患者,但在临床环境中尚没有有效的治疗选择来防止AAA的进展或消退。分子生物学的最新进展已导致在AAA形成过程中鉴定了几个重要的分子,包括microRNA和转录因子。使用核酸药物调节这些因子有望成为AAA的新型治疗选择。核酸药物可以序列特异性方式与靶标因子,mRNA,microRNA和转录因子结合,导致靶标分子在转录或转录后水平丧失功能。值得注意的是,使用诱饵策略抑制转录因子可通过调节与疾病进展相关的几种基因的表达来有效抑制实验性AAA的形成。这篇综述着重于使用核酸药物治疗AAA的分子疗法的最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号